SEC Form D filing

NurExone Biologic Inc., 2026-03-18

An SEC Form D private-offering notice from Technion City, Haifa, a $279,910 filer-stated offering target in Biotech. Filed 2026-03-18. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

NurExone Biologic Inc. site↗ Verified via SEC Form D

Publicly traded biotechnology company, listed as TSXV NRX and OTCQB NRXBF, developing exosome based regenerative therapies for spinal cord injury and other central nervous system conditions.

Filed 2026-03-18Filed to raise $279,910First money in 2026-03-10Raised so far $279,910HQ (as filed) Technion City, HaifaSector Biotech web-verified against the company’s own siteStage (inferred) Pre-seedCall status Non-US principal office
Source linked the Form D on EDGAR↗Website verified nurexone.com↗Named in the filing 6 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source